BIO.B (Bio-Rad Laboratories) ROCE % : -37.75% (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Bio-Rad Laboratories ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bio-Rad Laboratories's annualized ROCE % for the quarter that ended in Dec. 2024 was -37.75%.

Bio-Rad Laboratories ROCE % Historical Data

The historical data trend for Bio-Rad Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories ROCE % Chart

Bio-Rad Laboratories Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

50.81

37.00

-31.05

-6.48

-22.19

Bio-Rad Laboratories Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															15.25	16.83	-103.97	36.21	-37.75

Bio-Rad Laboratories ROCE % Calculation

Bio-Rad Laboratories's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-2293.6	/	( ( (12299.1 - 522.8)	+	(9364.1 - 467.8) )	/ 2 )
	=	-2293.6	/	( (11776.3	+	8896.3)	/ 2 )
	=	-2293.6	/	10336.3
	=	-22.19 %

Bio-Rad Laboratories's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-3586.928	/	( ( (10603.472 - 497.943)	+	(9364.1 - 467.8) )	/ 2 )
	=	-3586.928	/	( ( 10105.529	+	8896.3 )	/ 2 )
	=	-3586.928	/	9500.9145
	=	-37.75 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Bio-Rad Laboratories (NYSE:BIO.B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bio-Rad Laboratories ROCE % Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO.B) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIO:USA BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.